Your blood carries a quiet middleman that decides what happens to one of the most damaging amino acids in your body. When the system that handles it breaks down, the consequences ripple outward: harder arteries, higher heart attack and stroke risk, and altered chemistry in the aging brain. Most people have never heard of this molecule, and most standard panels skip it entirely.
Cystathionine sits at the exact junction where your cells either dispose of homocysteine safely or let it accumulate. In adults already worried about heart disease, plasma levels of cystathionine independently predict who will have a heart attack, who will have a stroke, and who will die earlier. Knowing your number gives you a window into a pathway that conventional cholesterol and inflammation tests cannot see.
Cystathionine is a sulfur-containing amino acid that forms when an enzyme called CBS (cystathionine beta-synthase) joins homocysteine to another amino acid, serine. A second enzyme, CSE (cystathionine gamma-lyase), then breaks cystathionine apart to make cysteine, the building block of your body's most important internal antioxidant (glutathione). Both enzymes need vitamin B6 to work.
This entire chain is called the transsulfuration pathway. It does three jobs at once: it gets rid of homocysteine before it damages blood vessels, it produces the raw material for antioxidant defenses, and it generates a small signaling gas (hydrogen sulfide) that helps blood vessels relax. When the pathway is working smoothly, cystathionine moves through quickly and stays at low levels. When something goes wrong upstream or downstream, cystathionine builds up or runs short, depending on where the bottleneck is.
In adults with suspected or established coronary heart disease, plasma cystathionine independently predicts the risk of a future heart attack. People in the highest quartile of cystathionine were roughly twice as likely to have an acute myocardial infarction (a heart attack) compared with people in the lowest quartile. This relationship held after accounting for traditional risk factors.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| About 6,700 adults with suspected or established coronary heart disease, followed prospectively across two cohorts | Highest quartile of plasma cystathionine versus lowest quartile | Roughly twice the risk of having a heart attack, even after adjusting for traditional cardiovascular risk factors |
Source: Dhar et al., International Journal of Cardiology, 2018.
What this means for you: if you already have known coronary disease or strong risk factors and your cystathionine is elevated, that pattern is a separate, additive signal of heart attack risk on top of what your cholesterol and blood pressure are telling you.
In a separate cohort of adults with suspected stable angina (chest pain that comes with exertion), higher plasma cystathionine independently predicted both total stroke and ischemic stroke (the type caused by a blocked blood vessel). People in the highest quartile had roughly two to two-and-a-half times the stroke risk of those in the lowest quartile, even after adjusting for other risk factors.
The same large cohort of about 6,700 adults with coronary heart disease showed that higher cystathionine independently predicted higher all-cause mortality, cardiovascular mortality, and non-cardiovascular mortality. The signal was not specific to heart disease deaths alone, suggesting cystathionine reflects a broader metabolic disturbance that affects how long people live.
Cystathionine itself is not believed to be the toxic agent. Elevated levels appear to mark a downstream bottleneck: the enzyme that should be breaking cystathionine apart is sluggish, often because vitamin B6 is low or because oxidative stress is interfering with the pathway. The result is less cysteine, less glutathione, and weaker antioxidant defense, all of which set the stage for arterial damage. In adults with stable angina, elevated cystathionine has been linked to lower glutathione levels, more endothelial dysfunction (impaired function of the thin cell layer that lines blood vessels), and more extensive coronary atherosclerosis.
In Alzheimer's disease, cystathionine in the temporal cortex of the brain has been measured at roughly 60 percent higher than in controls, while methionine levels run lower. This pattern suggests the transsulfuration pathway is shifted in Alzheimer brain tissue, possibly as a stressed compensation to keep producing cysteine and glutathione. In separate research, plasma and spinal-fluid cystathionine improved the accuracy of multi-marker models for predicting cognitive impairment, particularly in carriers of the APOE4 gene variant linked to Alzheimer risk.
In the European Prospective Investigation into Cancer and Nutrition (EPIC) study of about 575 cases and matched controls, biomarkers of the transsulfuration pathway were studied for links to renal cell carcinoma (the most common type of kidney cancer). Lower circulating vitamin B6 (in its active form) and lower cysteine were inversely linked to risk, suggesting that disturbances in this whole pathway, including cystathionine processing, may matter for kidney cancer development.
The flip-side problem is rare but important. People born with CBS deficiency (the inherited disease classical homocystinuria) cannot make cystathionine efficiently from homocysteine. Their blood shows high homocysteine, high or normal methionine, and low cystathionine. Untreated, the condition causes lens dislocation, skeletal abnormalities, learning difficulties, and a strong tendency toward dangerous blood clots. If you have a family history of homocystinuria or unexplained early thrombosis (blood clots) in close relatives, this pattern is what the test would catch.
Cystathionine is a research-stage marker. There are no universally agreed clinical cutpoints, no major guideline targets, and no consensus on what counts as optimal in a healthy person. The thresholds below come from how risk was sorted in the largest cardiovascular cohort. They are illustrative orientation drawn from research populations, not validated clinical targets, and your lab will likely report values in slightly different units. Use them only to understand where your number sits relative to the population studied.
| Tier | Where You Sit in the Population | What It Suggests |
|---|---|---|
| Lowest quartile | The bottom 25 percent of values in coronary heart disease cohorts | Reference group used in the heart attack and stroke risk studies. Very low values can also occur in inherited CBS deficiency, where they appear together with very high homocysteine. |
| Middle quartiles | The middle 50 percent | Intermediate range. Risk associations were modest in this band. |
| Highest quartile | The top 25 percent | Roughly twice the heart attack risk and roughly two to two-and-a-half times the stroke risk seen in adults with coronary heart disease, in the cohorts where this was measured. |
Source: risk thresholds derived from Dhar et al. cohorts of adults with coronary heart disease and adults with suspected stable angina, 2018 to 2019.
Compare your results within the same lab over time for the most meaningful trend. Different labs use different methods (most commonly liquid chromatography with mass spectrometry, a sensitive method for measuring small molecules), and absolute numbers can vary.
Because no single number carries a definitive clinical verdict for cystathionine, the trajectory matters more than any one reading. A baseline value tells you where you stand. A follow-up three to six months later tells you whether the pathway is moving in the right direction, especially if you are addressing vitamin B6 status or treating elevated homocysteine. Annual tracking after that gives you a personal trend line you can use to judge whether changes you make are translating into measurable shifts.
For a marker without standardized cutpoints, your own historical numbers become your best comparison. Start tracking now and you will have your own data to interpret as the science continues to mature.
An elevated cystathionine reading on its own should prompt a wider workup, not panic. The most useful companion tests are total homocysteine, vitamin B6, vitamin B12, folate, and a basic kidney function panel. Together these clarify whether the elevation reflects a fixable nutrient gap, kidney clearance, or a deeper pathway problem. If your homocysteine is also high and your B6 is low, vitamin B6 repletion is the obvious first step. If both cystathionine and homocysteine are elevated despite normal vitamin status, that is a pattern worth bringing to a clinician familiar with one-carbon metabolism (the network of chemical reactions that handles homocysteine, folate, and related B-vitamin pathways).
A low cystathionine paired with a markedly high homocysteine and a personal or family history of unusual blood clots, lens problems, or early cardiovascular events warrants evaluation by a metabolic specialist for inherited CBS deficiency.
Evidence-backed interventions that affect your Cystathionine level
Cystathionine is best interpreted alongside these tests.